Anti-SARS-CoV-2 Antibody Responses in Patients With IBD Treated With Biologics: Are We Finding CLARITY?

Chapman, Thomas P; Revés, Joana; Torres, Joana; Satsangi, Jack

Chapman, Thomas P; Revés, Joana; Torres, Joana; Satsangi, Jack.

Chapman TP; Department of Gastroenterology, St Richard's and Worthing Hospitals, University Hospitals Sussex, National Health Service Foundation Trust, West Sussex, United Kingdom; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.
Revés J; Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
Torres J; Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal; Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Satsangi J; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.

Gastroenterology ; 161(6): 2057-2059, 2021 12.

Article in English | MEDLINE | ID: covidwho-1415968

Subject(s)

Biological Products; COVID-19; Inflammatory Bowel Diseases; Antibody Formation; Biological Products/adverse effects; Humans; Inflammatory Bowel Diseases/drug therapy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / Inflammatory Bowel Diseases / COVID-19 Limits: Humans Language: English Journal: Gastroenterology Year: 2021 Document Type: Article Affiliation country: J.gastro.2021.09.019

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google